Literature DB >> 1569924

Interactions of cocaine with primary and secondary recognition sites on muscarinic receptors.

D D Flynn1, A A Vaishnav, D C Mash.   

Abstract

Several lines of evidence have suggested that muscarinic receptors may possess more than one ligand binding site. In this study, the interactions of cocaine with primary and secondary (allosteric) sites on muscarinic receptors in membrane homogenates from post-mortem human brainstem were examined. (-)-Cocaine inhibited the binding of the tritiated muscarinic antagonists N-methylscopolamine (NMS) and pirenzepine to an apparent single class of sites, with Ki values of 200-300 microM. The binding of the muscarinic agonist [3H]oxotremorine-M was inhibited with a similar Ki value (200 microM). (+)-Cocaine, although not the naturally occurring stereoisomer, was 10-20-fold more potent than (-)-cocaine in competing for binding to the primary muscarinic recognition site. The binding of cocaine was unaffected by guanine nucleotides or N-ethylmaleimide, consistent with its purported action as a competitive antagonist. Cocaine was not selective for muscarinic receptor subtypes. Rosenthal analysis of the [3H]NMS saturation binding data in the presence of increasing concentrations of either (-)-cocaine or (+)-cocaine indicated that both isomers produced an apparent competitive-like reduction in the [3H]NMS affinity. Schild regression analysis of the saturation binding data resulted in curvilinear plots suggestive of cooperative or allosteric interactions of (-)-cocaine with the [3H]NMS-labeled receptors. The effects of (-)-cocaine on the kinetics of [3H]NMS binding were consistent with an allosteric interaction with the receptor. Increasing concentrations of cocaine markedly slowed the rate of [3H]NMS dissociation from the primary recognition site. The allosteric modulation of [3H] NMS binding by (-)-cocaine was abolished with increasing ionic strength. Taken together, these data demonstrate that (-)-cocaine interacts with primary and allosteric recognition sites on muscarinic receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569924

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Mechanisms of acute cocaine toxicity.

Authors:  Kennon Heard; Robert Palmer; Nancy R Zahniser
Journal:  Open Pharmacol J       Date:  2008

2.  Neural response to lidocaine in healthy subjects.

Authors:  Bryon Adinoff; Michael D Devous; Donald C Cooper; Susan E Best; Thomas S Harris; Mark J Williams
Journal:  Psychiatry Res       Date:  2009-06-28       Impact factor: 3.222

3.  Evidence for cocaine and methylecgonidine stimulation of M(2) muscarinic receptors in cultured human embryonic lung cells.

Authors:  Y Yang; Q Ke; J Cai; Y F Xiao; J P Morgan
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  Altered neural cholinergic receptor systems in cocaine-addicted subjects.

Authors:  Bryon Adinoff; Michael D Devous; Mark J Williams; Susan E Best; Thomas S Harris; Abu Minhajuddin; Tanya Zielinski; Munro Cullum
Journal:  Neuropsychopharmacology       Date:  2010-03-10       Impact factor: 7.853

Review 5.  The role of acetylcholine in cocaine addiction.

Authors:  Mark J Williams; Bryon Adinoff
Journal:  Neuropsychopharmacology       Date:  2007-10-10       Impact factor: 7.853

6.  Characterization of the prejunctional muscarinic receptors mediating inhibition of evoked release of endogenous noradrenaline in rabbit isolated vas deferens.

Authors:  U Grimm; H Fuder; U Moser; H G Bümert; E Mutschler; G Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

7.  Cocaine: mechanism of inhibition of a muscle acetylcholine receptor studied by a laser-pulse photolysis technique.

Authors:  L Niu; L G Abood; G P Hess
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

Review 8.  Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications.

Authors:  Yufeng Wei; Rameen Shah
Journal:  Pharmaceuticals (Basel)       Date:  2020-07-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.